Uncategorized
Isunakinra does not meet primary endpoint in phase 3 trial for allergic conjunctivitis
Isunakinra did not meet its primary endpoint of achieving statistically significant results in ocular itching in a phase 3 trial, according to a press release from Eleven Biotherapeutics. The phase 3 clinical trial included 258 patients with moderate to severe allergic conjunctivitis who were randomized to receive treatment with isunakinra (EBI-005) or vehicle control. Patients received treatment for 4 weeks.